Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Watts

Showing results (41-50 of 829) with videos related to

Pageof 83
Sort By:
Expert Opinion on Therapeutic Targets|January 18, 2007
MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?John R Burnett, Gerald F Watts
Expert Opinion on Pharmacotherapy|July 16, 2010
Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapiesDick C Chan, Gerald F Watts
The Clinical Biochemist. Reviews|June 3, 2008
HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular diseaseGerald F Watts, John R Burnett
The Review of Diabetic Studies : RDS|January 1, 2014
Endothelial dysfunction in diabetes: pathogenesis, significance, and treatmentSandra J Hamilton, Gerald F Watts
Annals of Clinical Biochemistry|November 1, 1987
A simple side-room test to screen for 'microalbuminuria' in diabetes mellitusB W Hodgson, G F Watts
Drugs & Aging|June 1, 1997
Management of lipid disorders in the elderlyD A Playford, G F Watts
Current Opinion in Lipidology|February 19, 2000
Fibrates, dyslipoproteinaemia and cardiovascular diseaseG F Watts, S B Dimmitt
The Medical Journal of Australia|October 16, 1995
Serum HDL cholesterol: should it be routinely measured?S B Dimmitt, G F Watts
Clinical Science (London, England : 1979)|January 10, 2008
Is adipose tissue lipolysis always an adaptive response to starvation?: implications for non-alcoholic fatty liver diseaseSeng Khee Gan, Gerald F Watts
Journal of Pharmaceutical Sciences|June 1, 1978
Synthesis of potential antineoplastic agents XXVI: 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]2-quinolizinone derivativesF D Popp, R F Watts
Pageof 83

Showing results (41-50 of 829) with videos related to

Sort By:
Pageof 83
Expert Opinion on Therapeutic Targets|January 18, 2007
MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?John R Burnett, Gerald F Watts
Expert Opinion on Pharmacotherapy|July 16, 2010
Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapiesDick C Chan, Gerald F Watts
The Clinical Biochemist. Reviews|June 3, 2008
HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular diseaseGerald F Watts, John R Burnett
The Review of Diabetic Studies : RDS|January 1, 2014
Endothelial dysfunction in diabetes: pathogenesis, significance, and treatmentSandra J Hamilton, Gerald F Watts
Annals of Clinical Biochemistry|November 1, 1987
A simple side-room test to screen for 'microalbuminuria' in diabetes mellitusB W Hodgson, G F Watts
Drugs & Aging|June 1, 1997
Management of lipid disorders in the elderlyD A Playford, G F Watts
Current Opinion in Lipidology|February 19, 2000
Fibrates, dyslipoproteinaemia and cardiovascular diseaseG F Watts, S B Dimmitt
The Medical Journal of Australia|October 16, 1995
Serum HDL cholesterol: should it be routinely measured?S B Dimmitt, G F Watts
Clinical Science (London, England : 1979)|January 10, 2008
Is adipose tissue lipolysis always an adaptive response to starvation?: implications for non-alcoholic fatty liver diseaseSeng Khee Gan, Gerald F Watts
Journal of Pharmaceutical Sciences|June 1, 1978
Synthesis of potential antineoplastic agents XXVI: 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]2-quinolizinone derivativesF D Popp, R F Watts
Pageof 83